Navigation Links
PSA Can Predicts The Treatment Response In Advanced Prostate Cancer

A new study that has been conducted by researchers from the University of Michigan (U-M) medical school states that patients with lower PSA levels, //7 months after therapy lived longer.

According to a new multicentre study that has been conducted by the Southwest Oncology Group and led by researchers at the U-M Comprehensive Cancer Centre, that has been published in the August 20th issue of the Journal of Clinical Oncology, has explained that a test that is usually done to detect prostate cancer could also help doctors to know when the treatment is working. They further mentioned that the level of the prostate specific antigen, or PSA, in man after seven months of hormone therapy for advanced prostate cancer might foretell how long he would survive.

The study evaluated 1,345 men with prostate cancer that had spread to distant parts of the body. The men were treated with seven months of androgen deprivation therapy, a treatment designed to block the effects of hormones on the cancer. PSA levels were monitored throughout the treatment. The researchers found that men whose PSA dropped below 4.0 ng/ml had a quarter the risk of dying compared to those whose PSA was more than 4.0.

“Our analysis showed that a low or undetectable PSA after seven months of androgen deprivation therapy is a powerful predictor of risk of death in patients with new metastatic prostate cancer. This could allow oncologists to identify patients who are unlikely to do well with this treatment long before they develop clinical signs of treatment resistance,” says lead study author Maha Hussain, M.D., professor of internal medicine at the U-M Medical School.

The researchers found 69 percent of the men maintained a PSA level of less than 4.0 ng/ml after seven months of treatment and 43 percent had an undetectable level of PSA at that time. Patients whose PSA was higher than 4.0 at the end of seven months survived 13 months, while patients whose PSA drop ped below 4.0 but above 0.2 lived 44 months and those whose PSA was undetectable, below 0.2 ng/ml, lived 75 months.

The men in the study were enrolled in a Phase III SWOG trial in which they would receive additional treatment after the seven months of initial hormone therapy. That study seeks to accrue 1,512 men. The patient's PSA level before beginning treatment must be at least 5.0 ng/ml to qualify for the study.

A PSA test measures the level in the blood of prostate specific antigen, an enzyme produced by the prostate gland. It is generally used as an initial screening test to detect prostate cancer.

“What is attractive about using PSA to predict survival in metastatic prostate cancer is that it is an easily measurable factor. These findings could help patients avoid ineffective treatment and could help researchers design further trials,” Hussain says.

Source: EurekAlrt.
'"/>




Related medicine news :

1. Restricted Activity Predicts Disability
2. Fitness Level Predicts Stroke
3. Being Teased Predicts Poor Psychological Functioning in Youth With Cleft Lip
4. Model Predicts Colon Cancer Inheritable Genetic Defects
5. Formula Predicts Osteoporotic Fracture Risk
6. Computer Tool Predicts Effectiveness Of Microbicides
7. New Genetic Test Predicts Eye-Cancer Patients Futures
8. Technology Predicts Outcome of Child Heart Surgery
9. A Secret Dossier Predicts Major Changes At NHS, England
10. Activation of a Particular Brain Region Predicts Altruism: Study
11. New Test Predicts CLL’s Sensitivity to Experimental Drug
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/10/2019)... ... , ... AltMed Florida , one of the fastest growing Medical Marijuana ... opening of its second MÜV™ Medical Cannabis Dispensary on the First Coast – scheduled ... Beach. , Located at Beach Plaza Shopping Center at the corner of Beach Boulevard ...
(Date:10/8/2019)... SAUSALITO, Calif. (PRWEB) , ... October 08, 2019 ... ... 2,100 stores - Kroger, Ralphs, QFC and Fred Meyer, King Sooper, Fry’s, Roundy’s, ... Paleo, Whole30 approved, dairy-free, grain-free & gluten-free. , “Ingredient purity and fresh ...
(Date:10/8/2019)... , ... October 08, 2019 , ... Dr. Amir HagShenas ... in San Jose, CA experience relief from this common and treatable condition. Dr. HagShenas’ ... to save adults from living with uncomfortable symptoms, including tender and bleeding gums, and ...
(Date:10/8/2019)... ... October 08, 2019 , ... PotentiaMetrics, an Austin, ... Henderson as Chief Medical Officer. Dr. Henderson will be responsible for the development ... Henderson previously served as Chair of both the Informatics Governance and the Inpatient ...
(Date:10/8/2019)... ... October 08, 2019 , ... Smile Brands Inc. has ... compensation monitoring site, Comparably. Smile Brands, a leading dental support organization with nearly 440 ... mission to deliver Smiles for Everyone®. The Happiness Award is the latest in a ...
Breaking Medicine News(10 mins):
(Date:10/19/2019)... ... October 18, 2019 , ... A new study conducted ... adalimumab use in pregnancy was not associated with an increased risk for adverse ... The findings were published today in the Public Library of Science ...
(Date:10/17/2019)... ... October 17, 2019 , ... Mount ... deadly pediatric nerve cancer, who would otherwise have no treatment options, according to ... of the most common and aggressive pediatric nervous system tumors and generally has ...
(Date:10/17/2019)... ... October 17, 2019 , ... The findings of a new study ... individuals studied could be caused by toxic chemicals rather than the inhalation of oily ... With E-Cigarette Use (Vaping): A Report of Eight Cases ,” by Sanjay Mukhopadhyay, MD, ...
Breaking Medicine Technology: